No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Care Facilities
Indraprastha Medical Corporation Limited functions as a prominent healthcare provider across India, delivering a vast array of hospital services. Its extensive medical and surgical departments encompass a wide spectrum of specialties, ranging from advanced interventions like robotic surgery, organ transplantation, and bone marrow transplants, to core areas such such as cardiology, oncology, neurology, orthopedics, and gastroenterology. The company also provides a full suite of diagnostic, preventive, and rehabilitative care, including laboratory and radiology services, internal medicine, pediatrics, women's health, and mental health support. Founded in 1983, its main operational base is situated in New Delhi, India.
www.delhi.apollohospitals.comNo one on the platform currently holds INDRAMEDCO.BO.
No tracked institution reports a position in INDRAMEDCO.BO as of their last filing.
No one on the platform has traded INDRAMEDCO.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 32.4% | 26.4% | 26.1% | — | — | — |
| Rev. Growth % | 9.3% | 19.3% | ||||
| Profit Margin % | 12.4% | 9.7% | 6.5% | |||
| Free Cash Flow Margin % | 8.7% | 8.4% | 6.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $15.8B | — | $22.50 | $22.50–$22.50 | — | 1 |
| 2028 | $16.8B | +6.3% | $24.40 | $24.40–$24.40 | — | 1 |
| 2029 | $8.4B | -49.6% | $5.21 | $5.21–$5.21 | — | 1 |
| 2030 | $9.0B | +6.2% | $5.22 | $5.22–$5.22 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-11-10 | $0.76 | $5.40 | +610.5% |
| 2025-08-06 | $1.16 | $5.60 | +382.8% |
| 2025-05-16 | $1.16 | $0.90 | -22.4% |
| 2025-02-03 | $0.76 | $3.58 | +371.1% |
| 2024-10-30 | $0.76 | $4.63 | +509.2% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| INDRAMEDCO.BOIndraprastha Medical Corporation Limited | $354.90 | +0.18% | $32.5B | — |
| AARTIDRUGS.BOAarti Drugs Limited | $426.85 | -0.32% | $39.0B | — |
| AARTIDRUGS.NSAarti Drugs Limited | $426.35 | -0.50% | $38.9B | — |
| DCAL.BODishman Carbogen Amcis Limited | $162.85 | -2.78% | $25.6B | — |
| DCAL.NSDishman Carbogen Amcis Limited |
| $163.16 |
| -2.45% |
| $25.6B |
| — |
| GUJTHEM.BOGujarat Themis Biosyn Limited | $428.45 | +1.20% | $46.7B | — |
| INNOVACAP.NSInnova Captab Limited | $1140.10 | -0.62% | $65.2B | — |
Source: Financial Modeling Prep · peers by sector/industry